Patients with CML in the lymphoid blastic phase have inferior response to anti-CD19 CAR T-cell therapy compared to de novo Ph-positive B cell acute lymphoblastic leukemia.

ABSTRACT:

SUBMITTER: Liu MJ 

PROVIDER: S-EPMC10897941 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature